The New York clinical-stage biopharmaceutical company is focused on central nervous system, neurological and psychiatric disorders. The compnay's SLS-002 intranasal ketamine depression drug is aimed at patients with Post-Traumatic Stress Disorder (PTSD) and major depressive disorder (MDD) at risk of committing suicide.
The call will feature a discussion with Dr David V Sheehan, the University Health Professor Emeritus at the University of South Florida College of Medicine, who will discuss the unmet medical needs in treating suicidal patients with depression and other mental health conditions.
Dr Sheehan has written over 550 abstracts and 300 publications including a bestseller 'The Anxiety Disease', which has sold over 500,000 copies.
He has been awarded over $20 million for 130 research grants and has provided expert testimony to the Unites States Congress..
He was elected as a member of the American College of Psychiatrists and is a Distinguished Life Fellow of the American Psychiatric Association and is a Charter Member of the National Academy of Inventors.
Raj Mehra, the chairman and CEO of Seelos, will also discuss the group's lead candidate, intranasal racemic ketamine SLS-002 drug for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
The call will be moderated by Mario Nacinovich, a member of the adjunct faculty at Boston University. He is also the founding editor of the Journal of Communication in Healthcare.
The call will take place on Tuesday, May 26 at 1pm Eastern Time. Domestic callers can dial-in using 877-407-0789, while international callers can dial 201-689-8562. The conference ID is 13704179 and the webcast can be found HERE.